GC녹십자 Upgrades ‘WAPPS-HEMO’ Software for Hemophilia Patients

GC녹십자 has announced the release of an upgraded version of ‘WAPPS-HEMO’, a personalized software for domestic hemophilia patients.

What is ‘WAPPS-HEMO’?

‘WAPPS-HEMO’ is a software that helps medical professionals predict the patient’s pharmacokinetic profile and determine the appropriate administration dosage and interval for GC녹십자’s hemophilia treatment drugs ‘Greengene F’ and ‘Greenmono’. It was launched by GC녹십자 for the first time among domestic pharmaceutical companies in 2022.

Benefits for Patients

Patients using ‘WAPPS-HEMO’ can proactively manage their disease by checking their predicted blood coagulation factor levels through a dedicated mobile application.

Upgraded Features

The recently upgraded ‘WAPPS-HEMO’ uses about four times more real-world data (RWD) than the existing population pharmacokinetic (PK) model, thereby increasing the accuracy of individual preventive treatment. In particular, the accuracy of preventive treatment for pediatric and elderly patients has greatly improved.

Expert Insights

Dr. Yoo Ki-young, Director of the Korea Hemophilia Foundation, said, “With the use of ‘WAPPS-HEMO’ in the medical field, the annual bleeding frequency of hemophilia patients has decreased, their quality of life has improved, and the understanding of PK-based preventive therapy has increased.” He added, “This upgrade enables more precise predictions, which we expect will greatly contribute to personalized treatment for each patient.”

Personalized Treatment

Recently, the method of determining the dosage of blood clotting factors for hemophilia patients has changed from based on body weight (kg) to based on individual pharmacokinetics (PK). Since the pharmacokinetic profiles of blood clotting factors, such as half-life, are very different for each hemophilia patient, there were many limitations in predicting individual dosage based on body weight.

Future Plans

Choi Bong-gyu, head of GC녹십자’s data science center, said, “We expect to increase medication compliance for domestic hemophilia patients through personalized treatment, reduce total medical costs by reducing bleeding rates, and improve the quality of life for patients.” He added, “We will continue to spare no effort in creating an environment where patients with rare diseases can receive the optimal treatment that suits them.”